PharmaFocus Today – Page 28 – media

A New Generation of 10-Billion-Level Anticoagulant Drug Is Coming

Anticoagulants occupy a unique niche on the global bestselling drugs ranking. Unaffected by sudden pandemics or short-lived market trends, they have long secured a core position in the global pharmaceutical market driven by rigid clinical demand. In 2025, apixaban ranked sixth globally with $14.4 billion in worldwide sales, earning its title as the undisputed “King of Anticoagulants”. This sales figure not only surpassed blockbuster oncology drugs such as Opdivo and daratumumab, but also exceeded popular chronic disease medications like dapagliflozin. Beneath this prosperity, however, patents are expiring, and the billion-dollar era of the “xaban” class is drawing to a close. Yet the anticoagulant sector will not halt its progress: a new generation of blockbuster drugs is on the horizon. / 01 / An Unmatched Commercial Logic The enormous size of the anticoagulant market is hardly surprising. As the name suggests, antithrombotic drugs inhibit thrombus formation, promote thrombolysis, or prevent ...
- Source: drugdu
- 187
- March 16, 2026
Hua Medicine’s Innovative Drug Approved for Launch in Hong Kong via “Direct Access” Pathway!

Recently, Dorzagliatin, an innovative type 2 diabetes drug developed by Hua Medicine, has been approved for marketing by the Office of Pharmaceutical Products, Department of Health, Hong Kong Special Administrative Region. It has become the first general drug (a widely used medicine for common diseases) approved under Hong Kong’s “1+” Fast Track Approval Mechanism for new drugs. In 2023, the Shanghai-based enterprise highlighted through this newspaper the difficulties faced by domestic innovative drugs in seeking market approval in Hong Kong. Today, its wish has been fulfilled, as the innovative drug has been approved via the “direct access” route in Hong Kong. Holding both mainland and Hong Kong drug registration certificates, the company plans to expand to Southeast Asia, opening up broad overseas markets for domestic innovative drugs. For a long time, Hong Kong implemented the “2+” Approval Mechanism, which required new drugs to be first launched in two “listed countries” ...
- Source: drugdu
- 142
- March 16, 2026
Huige Portfolio | Baitewei Medical Completes Nearly 100 Million Yuan Series B Financing to Accelerate Innovative Product Layout in Peripheral Vascular Intervention and Heart Failure Fields

Recently, Shenzhen Baitewei Medical Technology Co., Ltd. (“Baitewei Medical”) announced the completion of a nearly 100 million yuan Series B financing round. The round was led by Tasly Capital, with Qinzhi Capital as a co-investor, and Vision Capital acted as the exclusive financial advisor. The proceeds will mainly be used for new product R&D, production base construction and market expansion, accelerating the company’s layout of innovative products in peripheral vascular intervention and heart failure. Building a peripheral intervention product matrix, achieving domestic breakthroughs in multiple devices In the field of peripheral vascular intervention, Baitewei has established a full product matrix covering “thromboreduction + thrombectomy + access”, with multiple technologies at a leading domestic level. Several devices have achieved domestic breakthroughs and successfully obtained market approval. Meanwhile, a number of additional innovative products are in the clinical application and registration stage, forming a full-cycle and sustainable product R&D and commercialization ...
- Source: drugdu
- 174
- March 16, 2026
Fangda Pharma helps Jiminke’s Class 1 innovative drug, Jilemei®, obtain market approval.

Recently, Jilemei® (soximerexyl sulfate tablets), a Class 1 innovative drug supported by Fangda Pharmaceutical (Suzhou) Co., Ltd. in the clinical stage, has been granted priority review and approval by the National Medical Products Administration and conditionally approved for marketing . Developed by Zhejiang Hangyu Pharmaceutical, a subsidiary of Jiming Kexin , this drug is intended to treat adult patients with advanced non-small cell lung cancer ( NSCLC ) with murine sarcoma virus oncogene ( KRAS ) G12C mutation who have received at least one systemic therapy , providing a new treatment option for this lung cancer subtype with a well-defined molecular target. As a partner, Fangda’s team completed the production , quality release, and stability studies of Phase I and Phase II clinical samples , and provided integrated services such as clinical double-blind labeling , sample storage management , clinical drug delivery, and international transportation . With its efficient, professional, ...
- Source: drugdu
- 164
- March 13, 2026
Dexamethasone API Marketing Application Approved

March 13th – Cyto BiotechThe announcement stated that the company’s controlling subsidiary, Shandong Srui Pharmaceutical Co., Ltd., received a certificate from the National Medical Products Administration for dexamethasone, a chemical raw material.”Notification of Approval for Drug Marketing Application”. Dexamethasone is a long-acting glucocorticoid with anti-inflammatory, anti-allergic, and immunosuppressive effects. It is mainly used for allergic and autoimmune inflammatory diseases, such as connective tissue diseases, severe bronchial asthma, dermatitis, ulcerative colitis, acute leukemia, and malignant lymphoma. https://finance.eastmoney.com/a/202603133671477849.html
- Source: drugdu
- 145
- March 13, 2026
China’s first innovative drug prescription based on precise postoperative assessment for thyroid cancer

On March 11, China’s first innovative drug　　for precise postoperative assessment of differentiated thyroid cancer was launched.Human thyroid-stimulating hormone beta (Zesuning) for injection at the First Affiliated Hospital of Zhejiang University School of MedicineThe first prescription was issued by Jiangsu Provincial People’s Hospital . Thyroid cancer is one of the fastest-growing solid tumors in recent years. Differentiated thyroid cancers, such as papillary carcinoma and follicular carcinoma, account for over 90% of cases. These tumors generally have a good prognosis, with a 10-year survival rate exceeding 90%. However, a high survival rate does not mean “no management is needed.” Studies show that approximately 10%-30% of patients still face the risk of recurrence or metastasis during postoperative follow-up. Therefore, regular and standardized postoperative follow-up to monitor for residual lesions or signs of recurrence is crucial for improving the long-term quality of life for these patients. For patients who have undergone total resection of ...
- Source: drugdu
- 139
- March 13, 2026
The launch meeting for the research project on innovative chemical drugs for Alzheimer’s disease was held.

On the afternoon of March 12, an innovative drug led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, was launched.The launch meeting for the National Science and Technology Major Project on Drug Development, ” Research on Innovative Chemical Drugs for Anti-Alzheimer’s Disease Targeting New Mechanisms,” was held in Shanghai. This meeting was conducted strictly in accordance with the special project management standards, systematically deploying the project’s overall objectives, technical roadmap planning, task allocation, clinical research layout, and funding management throughout the entire process. (Wanbangde)(002082) The wholly-owned subsidiary Wanbangde Pharmaceutical Group, together with the project lead unit, cooperating research institutions and industry experts, gathered together to discuss the details of the project implementation and build consensus on research and development. Alzheimer’s disease is the most common type of dementia in clinical practice and also the most prevalent neurodegenerative disease. Its main manifestations include progressive decline in memory, judgment, ...
- Source: drugdu
- 271
- March 13, 2026
Announcement Regarding the Inclusion of its Innovative Drug HSK31679 Tablets in the Breakthrough Therapy Program

March 12 – Harscon Pharmaceutical…The company announced that on March 12, 2026, it learned that HSK31679 tablets were officially included in the “Breakthrough Therapy List” by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, making it the first THR-β agonist to be included in the Breakthrough Therapy List in China. Currently, no drugs are approved in China for the treatment of MASH (non-alcoholic steatohepatitis). The inclusion of HSK31679 tablets in the “Breakthrough Therapy List” will greatly promote the research and development of new drugs in this field and bring new hope for the treatment of MASH patients in my country. https://finance.eastmoney.com/a/202603123670377648.html
- Source: drugdu
- 180
- March 13, 2026
SHR-9803 for Injection Approved for Clinical Trials

On March 11, Hengrui Medicine (600276/01276) issued an announcement stating that the company recently received the “Drug Clinical Trial Approval Notice” for SHR-9803 for injection issued by the National Medical Products Administration, and will conduct clinical trials in the near future. This drug is a Class 1 therapeutic biological product.It can activate anti-tumor immune activity, specifically bind to and eliminate regulatory T cells within tumors, while reducing the impact on peripheral Tregs, aiming to improve the safety and efficacy of tumor treatment. To date, the cumulative R&D investment in SHR-9803 injection-related projects is approximately RMB 18.3 million (unaudited). In the first three quarters of 2025, Hengrui Medicine achieved revenue of RMB 23.188 billion and net profit attributable to the parent company of RMB 5.751 billion. https://finance.eastmoney.com/a/202603113668880571.html
- Source: drugdu
- 202
- March 12, 2026
Invests 5 million yuan to participate in the establishment of an investment fund to expand into the biopharmaceutical field

Lumay Pharmaceutical(300006) announced on March 12 that the company recently signed an agreement with Xi’an Wojie Private Equity Fund Management Co., Ltd. and Sansure Biotech.Several institutions, including a technology company, signed a partnership agreement to jointly establish Guangzhou Shengquan Baijie Venture Capital Fund Partnership (Limited Partnership). The fund aims to raise a total of RMB 150 million, of which the company, as a limited partner, will contribute RMB 5 million from its own funds, representing a 3.33% stake. The investment fund primarily invests in innovative biopharmaceuticals and medical devices .In vitro diagnosticsIn the life and health sectors, investments in these industries shall not be less than 60% of the fund’s total paid-in capital. The fund focuses on investing in Guangzhou’s strategic emerging industries and future industries, and has established a fund for seed companies in Guangzhou.Investment ratio requirements for early-stage and angel-stage projects. According to the announcement, the company’s investment ...
- Source: drugdu
- 142
- March 12, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.